The effect of Tamsulosin with or without Tolterodine in treatment of patients with symptomatic BPH in Aria and 22 Bahman hospital in 2012

Subject Areas : علوم پزشکی

Masoud Isapour ¹ , Mahsa Abdollahian Moghadam ²

1 - استادیار، دانشکده پزشکی، دانشگاه آزاد اسلامی مشهد، مشهد، ایران
2 - دانشجوی پزشکی، دانشکده پزشکی، دانشگاه آزاد اسلامی مشهد، مشهد، ایران

Received: 2017-06-05 Accepted : 2017-06-05 Published : 2013-05-22

Keywords: Prostatic hyperplasia, toltrodine, tamsulosin,

Abstract :

Background: Although voiding symptoms are classically related to BPH, as many as 50% of patients can experience irritative symptoms. We compared efficacy of tamsulosin with or without tolterodine in the treatment of patients with symptomatic  BPH (benign prostatic hyperplasia). Methods: seventy six patients who fulfilled the inclusion/ exclusion criteria were randomly divided into two groups of tamsulosin monotherapy (0/4 mg/day until 12 weeks) versus tamsulosin (0/4 mg/day until 12 weeks) and Tolterodine (2mg BID for 4 weeks) combination therapy. Therapeutic efficacy was analyzed using international prostate symptom score (IPSS) before and after 4 weeks of treatment. Results: Total IPSS was significantly improved in both groups. Although Combination therapy group showed better improvement in all Lower urinary tract symptoms, but the difference between 2 groups was significant considering complete emptying of bladder, voiding duration less than 2 hours and weak stream (P<0/05). Conclusion: Addition of Tolterodin to Tamsulosin is effective in improving lower urinary tract symptoms in patients with benign prostatic hyperplasia.  

References:

 

1. کاویانی ع. گلشن ع. جوانمرد ب. لطفی ب. زاهدی ب. امنیت و کارایی درمان ترکیبی انتی کولینرژیک و الفا بلوکردر معالجه ی هایپر پلازی خوش خیم پروستات. مجله ی علمی پژوهشی دانشگاه علوم پزشکی ارتش جمهوری اسلامی ایران زمستان 1388؛ سال هفتم (شماره4): 267_271


2. Roehborn CG, Connell J. epidemiology, pathophysiology & natural history of prostate hyperplasia. In:Inp.c.wals(Ed.), campbells urology .10th Ed. Philadelphia: saunders;2012.p. 2572-2586


3. Kaplan SA.Roehrborn CG. Chancellor M. Carlosson M. Bavendam T. Guan Z. Extended_realeasetolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effect on Urinary Symptoms accessed by the International Prostate Symptom Score. BJU Lnt. 2008 Nov; 102 (9).


4. Sun YM.Gu WD. Lu JW. LengJ.Bo JJ. Liu DM. Combination of tamsulosin and tolterodine alleviates refractory lower urinary tract symptoms in male patients. Zhonghua Nan KeXue. 2010 Sep; 16(9): 790_3.


5. Wu ZL.Geng H. Combination of tolterodin and tamsulosin for benign prostatic hyperplasia.Zhonghua Nan KeXue.2009 Jul; 15(7): 639_41.


6. Kaplan SA.Roehrborn CG. Rovnern ES.Carlsson M. Bavendam T. Guan ZH. Tolterodine and Tamsulosin for treatment of men with Lower Urinary TractSymptoms and Overactive Bladder. 2006; 296(19): 2319_2328.


7. کشوری ملیحه,تقوی رضوی زاده رحیم,شکیبا بهنام. اثر دسموپرسین خوراکی بر شب ادراری ناشی از بزرگی خوش خیم پروستات: نتایج کوتاه مدت و بلندمدت. مجله پزشکی دانشگاه علوم پزشکی ارومیه. پاییز 1389; 21(3):221-227.


8. پوررضا فرشید,مختاری غلامرضا,فلاحتکار سیاوش,روشنی علی,حسینی شریفی سیدحسین,عمادی سیده عاطفه,اکبرپور مرضیه,ربیعی پرهام. بررسی تاثیر افزودن سیلدنافیل به داروهای آلفا بلوکر در رفع زود هنگام احتباس ادراری حاد در هیپر پلازی خوش خیم پروستات. مجله دانشگاه علوم پزشکی گیلان. زمستان 1387; 17(68):57-62.


9. Gao ZW, Xin SY, Zhang JG, Ren XQ, Shang YF, Zhang W, Li HB, Xiao F, Shao CS.[Efficacy of combination therapy of tamsulosin and solifenacin for mild and moderate benign prostatic hyperplasia with overactive bladder].Zhonghua Nan Ke Xue. 2014 Mar;20(3):239-43.


10. Verheggen BG¹, Lee R, Lieuw On MM, Treur MJ, Botteman MF, Kaplan SA, Trocio JN. Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder.J Med Econ. 2012;15(3):586-600.


11. Roehrborn CG¹, Kaplan SA, Kraus SR, Wang JT, Bavendam T, Guan Z. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.Urology. 2008 Nov;72(5):1061-7; discussion 1067.


12. Rovner ES¹, Kreder K, Sussman DO, Kaplan SA, Carlsson M, Bavendam T, Guan Z.Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.J Urol. 2008 Sep;180(3):1034-41.